Downstaging of a Gastroenteropancreatic Neuroendocrine Tumor after Combination Therapy of Temozolomide, Bevacizumab and Long-Acting Somatostatin Analogs

S. Antoniou, G. Kanakis, A. Zilos, D. Thomas, N. Tzavaris, A. Ntokou, Theofanis Floros, A. Koumarianou, G. Kaltsas

Introduction

Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.

Downstaging of a Gastroenteropancreatic Neuroendocrine Tumor after Combination Therapy of Temozolomide, Bevacizumab and Long-Acting Somatostatin Analogs

Downstaging of a Gastroenteropancreatic Neuroendocrine Tumor after Combination Therapy of Temozolomide, Bevacizumab and Long-Acting Somatostatin Analogs

Introduction

Photostream